onc.ai: Advancing Oncology Decision-Making with AI

onc.ai is a cutting-edge AI-powered digital health platform dedicated to improving cancer treatment decisions, particularly in metastatic lung and kidney cancers. By leveraging a comprehensive real-world oncology dataset—including diagnostic imaging, electronic medical records, lab results, and genomics—it applies advanced deep learning to extract critical biomarkers from routine CT scans without manual annotation. The platform delivers fast, actionable insights within 24 hours, enabling high-precision survival prediction, early therapeutic response assessment, patient stratification, and enhanced clinical trial design. With FDA Breakthrough Device Designation for its Serial CTRS product and validation from leading institutions like Flatiron Health, Pfizer, and GSK, onc.ai stands at the forefront of AI in oncology. Its intuitive visual and tabular outputs provide structured, standardized scores at both individual and cohort levels, all processed securely and de-identified. Designed for pharma clinical development and medical oncologists, onc.ai is a transformative tool for data-driven cancer care and research.

Key Features:

• AI-driven clinical outcome prediction for metastatic lung and kidney cancer
• Deep learning models that extract imaging biomarkers from routine CT scans
• Automatic quality control for baseline and follow-up scans
• Secure, de-identified data processing
• Structured and standardized biomarker scores (tumor burden, vascularity, body composition, organ morphology, radiomic signature, multi-site tumor burden, vascular structure)
• Patient-specific prognostic risk scores and 12-month overall survival risk stratification
• Support for clinical trial design, patient stratification, and treatment arm balancing
• Fast report generation within 24 hours
• Validation on real-world datasets and clinical trials (Flatiron Health, Pfizer, GSK)
• Investigational use only (under FDA review)

Pricing: Currently, onc.ai does not publicly disclose pricing details; however, its focus on pharma and clinical applications suggests a subscription or enterprise licensing model tailored to healthcare organizations and biopharmaceutical partners.

Conclusion: onc.ai is a powerful, scientifically validated AI platform redefining oncology decision-making with deep insights from real-world data—ideal for advancing cancer research, clinical development, and personalized treatment strategies.